Drugs Made In America Acquisition (DMIIR) Shares Outstanding (2024 - 2026)

Drugs Made In America Acquisition (DMIIR) has reported Shares Outstanding (Entity) for 2 consecutive years, with $13.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Shares Outstanding (Entity) fell 4.7% year-over-year to $13.7 million; the TTM figure through Dec 2025 stood at $13.7 million (down 4.7% YoY), while the FY2025 annual figure was $13.7 million, down 4.7% from the prior year.
• Shares Outstanding (Entity) rose to $13.7 million in Q4 2025 per DMIIR's latest filing, from $12.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $14.4 million in Q4 2024 and bottomed at $12.6 million in Q3 2025.